Australia Markets closed
  • ALL ORDS

    7,248.10
    -193.40 (-2.60%)
     
  • ASX 200

    6,961.60
    -177.90 (-2.49%)
     
  • AUD/USD

    0.7157
    +0.0002 (+0.0215%)
     
  • OIL

    85.33
    -0.27 (-0.32%)
     
  • GOLD

    1,849.10
    -3.40 (-0.18%)
     
  • BTC-AUD

    51,439.77
    -12.65 (-0.02%)
     
  • CMC Crypto 200

    831.82
    +21.22 (+2.62%)
     
  • AUD/EUR

    0.6329
    +0.0005 (+0.07%)
     
  • AUD/NZD

    1.0698
    +0.0008 (+0.08%)
     
  • NZX 50

    12,157.43
    +29.23 (+0.24%)
     
  • NASDAQ

    14,149.12
    -289.28 (-2.00%)
     
  • FTSE

    7,371.46
    -122.67 (-1.64%)
     
  • Dow Jones

    34,297.73
    -66.77 (-0.19%)
     
  • DAX

    15,123.87
    -480.03 (-3.08%)
     
  • Hang Seng

    24,243.61
    -412.89 (-1.67%)
     
  • NIKKEI 225

    27,178.14
    +46.80 (+0.17%)
     

These 2 Nasdaq Biotechs Are Bucking the Market Downtrend

·3-min read
These 2 Nasdaq Biotechs Are Bucking the Market Downtrend
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • MOLN.SW
  • IMGN
  • COMP

The stock market saw its recent volatility continue on Tuesday morning, as ongoing concerns about longer-term impacts of new COVID-19 variants weighed on market sentiment. As of 11:30 a.m. ET, the Nasdaq Composite (NASDAQINDEX: ^IXIC) had given up early gains and was down 204 points to 15,579. Immunogen (NASDAQ: IMGN) and Molecular Technology (NASDAQ: MOLN) were big gainers on the Nasdaq Tuesday morning, and the news they announced could keep boosting their shares for some time to come.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting